LLY

1,129.01

+4.1%↑

JNJ

230.66

-0.67%↓

ABBV

218.06

+1.35%↑

UNH

385.38

+0.74%↑

MRK

120.4

-0.77%↓

LLY

1,129.01

+4.1%↑

JNJ

230.66

-0.67%↓

ABBV

218.06

+1.35%↑

UNH

385.38

+0.74%↑

MRK

120.4

-0.77%↓

LLY

1,129.01

+4.1%↑

JNJ

230.66

-0.67%↓

ABBV

218.06

+1.35%↑

UNH

385.38

+0.74%↑

MRK

120.4

-0.77%↓

LLY

1,129.01

+4.1%↑

JNJ

230.66

-0.67%↓

ABBV

218.06

+1.35%↑

UNH

385.38

+0.74%↑

MRK

120.4

-0.77%↓

LLY

1,129.01

+4.1%↑

JNJ

230.66

-0.67%↓

ABBV

218.06

+1.35%↑

UNH

385.38

+0.74%↑

MRK

120.4

-0.77%↓

Inicio・Lista de Acciones・Kura Oncology Inc

Kura Oncology Inc

Abierto

SectorSanidad

10.07 -4.1

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

9.86

Máximo

10.54

Métricas clave
By Trading Economics
Ingresos	7.7M -73M
Ventas	929K 18M
BPA	-0.828
Margen de beneficios	-401.495
Empleados	260
EBITDA	7.4M -78M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+170.03% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	159M 1B
Apertura anterior	14.17
Cierre anterior	10.07

Noticias sobre sentimiento de mercado

By Acuity

26%

74%

47 / 344 Clasificación en Healthcare

Kura Oncology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

27 may 2026, 21:33 UTC

Ganancias

Correction to Salesforce 1Q Sales, Profit Rise Article

27 may 2026, 21:00 UTC

Adquisiciones, fusiones, absorciones

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 may 2026, 20:18 UTC

Ganancias

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 may 2026, 23:49 UTC

Charlas de Mercado

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 may 2026, 23:39 UTC

Charlas de Mercado

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 may 2026, 23:34 UTC

Charlas de Mercado

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 may 2026, 23:34 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

27 may 2026, 23:08 UTC

Charlas de Mercado

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 may 2026, 22:21 UTC

Charlas de Mercado

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 may 2026, 21:29 UTC

Acciones populares

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 may 2026, 21:08 UTC

Ganancias

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 may 2026, 21:02 UTC

Ganancias

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 may 2026, 20:59 UTC

Adquisiciones, fusiones, absorciones

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 may 2026, 20:55 UTC

Ganancias

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 may 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

27 may 2026, 20:48 UTC

Ganancias

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 may 2026, 20:45 UTC

Ganancias

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 may 2026, 20:34 UTC

Adquisiciones, fusiones, absorciones

Webster Financial Stockholders Approve Sale to Banco Santander

27 may 2026, 20:32 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 may 2026, 20:32 UTC

Adquisiciones, fusiones, absorciones

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 may 2026, 20:32 UTC

Adquisiciones, fusiones, absorciones

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 may 2026, 20:30 UTC

Ganancias

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 may 2026, 20:30 UTC

Adquisiciones, fusiones, absorciones

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 may 2026, 20:22 UTC

Ganancias

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 may 2026, 20:16 UTC

Ganancias

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 may 2026, 20:13 UTC

Ganancias

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 may 2026, 20:13 UTC

Ganancias

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 may 2026, 20:13 UTC

Ganancias

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 may 2026, 20:12 UTC

Ganancias

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 may 2026, 20:12 UTC

Ganancias

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Comparación entre iguales

Cambio de precio

Kura Oncology Inc previsión

Precio Objetivo

By TipRanks

170.03% repunte

Estimación a 12 Meses

Media 28.11 USD 170.03%

Máximo 40 USD

Mínimo 15 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kura Oncology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Kura Oncology Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

47 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.